[
  {
    "path":[
      907040000,
      802000000
    ],
    "contexts":[
      " 9 Information to be included on the main label (7) Subject to subsection 9(9), if the medicine is intended to be, or is, registered goods, then: (d) if subsection 8(2) applies and the medicine: (i) includes one or more active ingredients, the name of which includes descriptors (for example chemical salts or hydration states) that are not therapeutically relevant; and (ii) the name and quantity or proportion of each of those active ingredients is displayed in accordance with subsection 8(2), then the name of the therapeutically active moiety(ies) of the active ingredient may be displayed on the main label on the primary pack, instead of the name of the active ingredient, if: (iii) this is in a text size of not less than 3.0 millimetres; and (iv) no quantity or proportion information is displayed for any of the active ingredients in the medicine.",
      " 8 Information to be included on the label (2) (f) The presentation of the critical health information, and any information mentioned in paragraphs 8(2)(c), 8(2)(d) or 8(2)(e) that is included, must be presented in black or other dark coloured texts, using only one colour, on a white or other contrasting background."
    ]
  },
  {
    "path":[
      908030000,
      907000000
    ],
    "contexts":[
      " 9 Information to be included on the main label (8) Where a medicine is: (c) (i) the total number of active ingredients in the different formulations in the composite pack or medicine kit are to be counted; and (ii) if the same active ingredient is contained in two or more formulations in the composite pack or medicine kit, each of those active ingredients is to be counted separately, for the purposes of determining if paragraph 9(6)(b) applies to the composite pack or medicine kit, or which paragraph in subsection 9(7) applies to the composite pack or medicine kit; and",
      " 9 Information to be included on the main label (7) Subject to subsection 9(9), if the medicine is intended to be, or is, registered goods, then: (d) if subsection 8(2) applies and the medicine: (i) includes one or more active ingredients, the name of which includes descriptors (for example chemical salts or hydration states) that are not therapeutically relevant; and (ii) the name and quantity or proportion of each of those active ingredients is displayed in accordance with subsection 8(2), then the name of the therapeutically active moiety(ies) of the active ingredient may be displayed on the main label on the primary pack, instead of the name of the active ingredient, if: (iii) this is in a text size of not less than 3.0 millimetres; and (iv) no quantity or proportion information is displayed for any of the active ingredients in the medicine."
    ]
  },
  {
    "path":[
      802060000,
      802050000
    ],
    "contexts":[
      " 8 Information to be included on the label (2) (f) The presentation of the critical health information, and any information mentioned in paragraphs 8(2)(c), 8(2)(d) or 8(2)(e) that is included, must be presented in black or other dark coloured texts, using only one colour, on a white or other contrasting background.",
      " 8 Information to be included on the label (2) (e) If information other than the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be included, it must be placed under the \u2018Other information\u2019 heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b) and must not contain any additional information other than: A. requirements relating to storage conditions B. information about package features to prevent tampering C. names of all excipients D. sponsor or distributor contact details."
    ]
  },
  {
    "path":[
      907030000,
      901030000
    ],
    "contexts":[
      " 9 Information to be included on the main label (7) Subject to subsection 9(9), if the medicine is intended to be, or is, registered goods, then: (c) where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required; or",
      " 9 Information to be included on the main label (1) Subject to the qualifications and special requirements specified in this section and section 10 of this Order, the information on the main label of the medicine must include: (c) the quantity or proportion of all active ingredients in the medicine; and"
    ]
  },
  {
    "path":[
      1009020000,
      900000000
    ],
    "contexts":[
      " 10 Qualifications and special requirements (9) Strip, blister and dial dispenser packs (b) If, in relation to a medicine referred to in (a) there are: (i) four or more active ingredients in the medicine and the medicine is intended to be, or is, registered goods; or (ii) two or more active ingredients in the medicine and the medicine is intended to be, or is, listed goods, then, in relation to compliance of the label on the strip, blister or dial dispenser pack with sections 8 and 9, it shall be sufficient if the following information is displayed: (iii) the name of the medicine; and (iv) the batch number of the medicine preceded by the batch number prefix; and (v) the expiry date of the medicine preceded by the expiry date prefix; and (vi) the name of the sponsor or distributor, or registered trademark if it readily identifies the sponsor or distributor of the medicine.",
      " 9 Information to be included on the main label (6) If the medicine is intended to be, or is, listed goods: (a) if the medicine is a sunscreen preparation - the name of every active ingredient, together with the quantity or proportion of every active ingredient, and the name of the dosage form, may appear on a side panel or side label or on a rear panel or rear label; or"
    ]
  },
  {
    "path":[
      1005000000,
      900000000
    ],
    "contexts":[
      " 10 Qualifications and special requirements (5) Sunscreen preparations If: (b) is enclosed in a container with a capacity of not more than 25 millilitres, then, in relation to compliance with sections 8 and 9, it shall be sufficient if (i) the sun protection factor is displayed in a text size of not less than 1.5 millimetres; and (ii) all other information is displayed in a text size of not less than 1.0 millimetres.",
      " 9 Information to be included on the main label (3) Subject to paragraph (c), the name of the medicine and the name(s) of active ingredient(s) on the main label must: (b) not be separated by any text or graphics, except where additional information is: (i) required or permitted by: (A) paragraph 11(2)(h); or (B) subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A); or (C) subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit;"
    ]
  },
  {
    "path":[
      907020000,
      802000000
    ],
    "contexts":[
      " 9 Information to be included on the main label (7) Subject to subsection 9(9), if the medicine is intended to be, or is, registered goods, then: (b) where the medicine contains four or more active ingredients and subsection 8(2) does not apply, then the names and the quantities or proportions of the active ingredients may be included on a side panel or side label or on a rear panel or rear label, when displayed in a text size of not less than 2.5 millimetres; or",
      " 8 Information to be included on the label (2) (e) If information other than the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be included, it must be placed under the \u2018Other information\u2019 heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b) and must not contain any additional information other than: A. requirements relating to storage conditions B. information about package features to prevent tampering C. names of all excipients D. sponsor or distributor contact details."
    ]
  },
  {
    "path":[
      601150000,
      801030000
    ],
    "contexts":[
      "6 Interpretation. \"critical health information\" means information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of this Order, that is critical for safe use of medicines that are self-selected by a consumer;",
      " 8 Information to be included on the label (1) Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include: (c) the quantity or proportion of all active ingredients in the medicine; and"
    ]
  },
  {
    "path":[
      1102070000,
      1102060000
    ],
    "contexts":[
      " 11 How information is to be expressed (2) Expression of quantity or proportion of active ingredients Subject to paragraph 11(2)(i) and subsection 11(3) below, the quantity or proportion of an active ingredient to be included on a label must be expressed: (g) for preparations applied to the skin and mucous membranes, other than those covered by paragraph (f) - as a percentage expressed in terms of w\/w, w\/v, v\/v or v\/w, as appropriate, or as the weight or volume in a stated weight or volume of the medicine, as appropriate;",
      " 11 How information is to be expressed (2) Expression of quantity or proportion of active ingredients Subject to paragraph 11(2)(i) and subsection 11(3) below, the quantity or proportion of an active ingredient to be included on a label must be expressed: (f) for pressurised metered dose inhalers, dry powder inhalers and other metered dose products such as nasal sprays, the quantity of the active ingredient is: (i) the quantity delivered per actuation; or where the Secretary, when registering the medicine, has accepted that the dose of products containing those active ingredients was clinically established as the metered dose, then: (ii) the quantity metered per actuation;"
    ]
  },
  {
    "path":[
      805000000,
      801000000
    ],
    "contexts":[
      " 8 Information to be included on the label (5) If the container is enclosed in a delivery device such that it cannot be removed, the information required on its label under subsection 8(1) must be applied on the delivery device and not the container.",
      " 8 Information to be included on the label (1) Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include: (k) relevant warning statements, where these are required in relation to a particular medicine or in specified circumstances applying to a particular medicine, such as the following: (i) where the medicine is for external use the required statement is \u2018Caution: Not to be Swallowed\u2019 or \u2018For External Use Only\u2019 or words to this effect; (ii) where: (A) the medicine is for oral use; and (B) the medicine contains active ingredient(s) included in category 'B' (including 'B1', 'B2', 'B3') or category 'C' in the document titled \u2018Prescribing medicines in pregnancy database\u2019 published on the TGA website as on the date of commencement of this Order; and (C) the medicine is not subject to other specific warning statement(s) relating to use during pregnancy, the required statement is: \u2018If pregnant or likely to become pregnant, consult a pharmacist or a doctor before use\u2019 or words to this effect; and (iii) where: (A) the medicine is a registered goods for oral use; and (B) the medicine contains active ingredient(s) included in category \u2018D\u2019 (except nicotine for smoking cessation) in the document titled \u2018Prescribing medicines in pregnancy database\u2019 published on the TGA website as at the date of commencement of this Order; and (C) the medicine is not subject to other specific warning statements(s) relating to use during pregnancy, the required statement is \u2018Do not use this medicine if pregnant or likely to become pregnant\u2019 or words to this effect; and"
    ]
  },
  {
    "path":[
      1008030000,
      900000000
    ],
    "contexts":[
      " 10 Qualifications and special requirements (8) Individually wrapped medicines (c) Where: (i) a medicine consists of dry herbs contained in individual bags and the bag is retained around the herbs during preparation; (ii) the bags are contained in a primary pack, the label of which complies with the requirements of this Order, then the individual bag need not be labelled with the information referred to in sections 8 and 9.",
      " 9 Information to be included on the main label (10) Subsection 9(9) does not apply: (a) where the medicine is supplied in a small container; or"
    ]
  },
  {
    "path":[
      905030000,
      901030000
    ],
    "contexts":[
      " 9 Information to be included on the main label (5) If the medicine contains: (c) if the medicine is intended to be, or is, registered goods, and (i) subsection 8(2) does not apply, then the names, and quantities or proportions, of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres; or (ii) subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.",
      " 9 Information to be included on the main label (1) Subject to the qualifications and special requirements specified in this section and section 10 of this Order, the information on the main label of the medicine must include: (c) the quantity or proportion of all active ingredients in the medicine; and"
    ]
  },
  {
    "path":[
      1009010000,
      900000000
    ],
    "contexts":[
      " 10 Qualifications and special requirements (9) Strip, blister and dial dispenser packs (a) Subject to paragraph (b), if: (i) a medicine consists of individual dosage units such as tablets, capsules, pills, pastilles, cachets, lozenges, pessaries, suppositories or single doses of powder; and (ii) two or more dosage units are individually enclosed in a strip, blister or dial dispenser pack such that the dosage units can only be extracted individually; and (iii) the strip, blister or dial dispenser pack is enclosed in a primary pack, the label of which complies with sections 8 and 9, then, in relation to compliance of the label on the strip, blister or dial dispenser pack with sections 8 and 9, it shall be sufficient if the following information is displayed: (iv) the name of the medicine; and (v) the name(s) of all active ingredients in the medicine; and (vi) the quantity or proportion of all active ingredients in the medicine; and (vii) the batch number of the medicine preceded by the batch number prefix; and (viii) the expiry date of the medicine preceded by the expiry date prefix; and (ix) the name of the sponsor or distributor, or registered trademark if it readily identifies the sponsor or distributor of the medicine.",
      " 9 Information to be included on the main label (9) If the medicine is intended to be, or is, registered goods, and the name of an active ingredient included in the medicine comprises an ingredient name specified in Schedule 2 to this Order, either alone or in combination with any other descriptors, then the names of all active ingredients in the medicine, together with their quantity or proportion, must be displayed in a text size of not less than 2.5 millimetres."
    ]
  },
  {
    "path":[
      1001000000,
      1007000000
    ],
    "contexts":[
      " 10 Qualifications and special requirements (1) Preparations for ophthalmic use In addition to the requirements of sections 8 and 9 above, if a medicine is a preparation for ophthalmic use, the label on the container and on the primary pack or, where subsection 10(7) applies, the primary pack, must include: (c) if the medicine is for multidose use - a statement to the effect that \u2018the medicine should not be used more than four weeks\u2019, or such shorter period as specified in the approved product details in relation to the medicine, after the container is first opened;",
      " 10 Qualifications and special requirements (7) Small containers If: (d) the name(s) of all active ingredients in the medicine, unless there are four or more active ingredients; and the following information is displayed in a text size of not less than 1.5 millimetres:"
    ]
  },
  {
    "path":[
      905030000,
      802000000
    ],
    "contexts":[
      " 9 Information to be included on the main label (5) If the medicine contains: (c) if the medicine is intended to be, or is, registered goods, and (i) subsection 8(2) does not apply, then the names, and quantities or proportions, of the active ingredients must be displayed on the side or rear panel or label in a text size of not less than 2.5 millimetres; or (ii) subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required.",
      " 8 Information to be included on the label (2) (c) The information provided under paragraph 8(2)(b)(i) may include words describing the purpose of the active ingredient(s) by indicating the pharmacological category or the principal intended actions that are not required by this Order."
    ]
  },
  {
    "path":[
      907030000,
      901020000
    ],
    "contexts":[
      " 9 Information to be included on the main label (7) Subject to subsection 9(9), if the medicine is intended to be, or is, registered goods, then: (c) where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required; or",
      " 9 Information to be included on the main label (1) Subject to the qualifications and special requirements specified in this section and section 10 of this Order, the information on the main label of the medicine must include: (b) the name(s) of all active ingredients in the medicine; and"
    ]
  },
  {
    "path":[
      1007000000,
      1001000000
    ],
    "contexts":[
      " 10 Qualifications and special requirements (7) Small containers If: (d) the name(s) of all active ingredients in the medicine, unless there are four or more active ingredients; and the following information is displayed in a text size of not less than 1.5 millimetres:",
      " 10 Qualifications and special requirements (1) Preparations for ophthalmic use In addition to the requirements of sections 8 and 9 above, if a medicine is a preparation for ophthalmic use, the label on the container and on the primary pack or, where subsection 10(7) applies, the primary pack, must include: (e) if the medicine consists of a solid ophthalmic medicine for preparing eye drops for multidose use - the words \u2018for eye drops\u2019."
    ]
  },
  {
    "path":[
      1009010000,
      800000000
    ],
    "contexts":[
      " 10 Qualifications and special requirements (9) Strip, blister and dial dispenser packs (a) Subject to paragraph (b), if: (i) a medicine consists of individual dosage units such as tablets, capsules, pills, pastilles, cachets, lozenges, pessaries, suppositories or single doses of powder; and (ii) two or more dosage units are individually enclosed in a strip, blister or dial dispenser pack such that the dosage units can only be extracted individually; and (iii) the strip, blister or dial dispenser pack is enclosed in a primary pack, the label of which complies with sections 8 and 9, then, in relation to compliance of the label on the strip, blister or dial dispenser pack with sections 8 and 9, it shall be sufficient if the following information is displayed: (iv) the name of the medicine; and (v) the name(s) of all active ingredients in the medicine; and (vi) the quantity or proportion of all active ingredients in the medicine; and (vii) the batch number of the medicine preceded by the batch number prefix; and (viii) the expiry date of the medicine preceded by the expiry date prefix; and (ix) the name of the sponsor or distributor, or registered trademark if it readily identifies the sponsor or distributor of the medicine.",
      " 8 Information to be included on the label (4) If the information required on the label on the container is obscured by intermediate packaging, then the label on the intermediate packaging must include: (b) the name(s) of all active ingredients in the medicine; and"
    ]
  },
  {
    "path":[
      910020000,
      911000000
    ],
    "contexts":[
      " 9 Information to be included on the main label (10) Subsection 9(9) does not apply: (b) where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(11) and Part 1 of Schedule 2\u2014after 30 April 2026; or",
      " 9 Information to be included on the main label (11) An active ingredient specified in Part 1 of Schedule 2, either alone or in combination with any other descriptors, may be included on the main label of a medicine containing that ingredient as specified in that Part for medicine released for supply before 1 May 2026."
    ]
  },
  {
    "path":[
      907030000,
      802000000
    ],
    "contexts":[
      " 9 Information to be included on the main label (7) Subject to subsection 9(9), if the medicine is intended to be, or is, registered goods, then: (c) where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required; or",
      " 8 Information to be included on the label (2) (b) The critical health information must be presented under appropriate headings and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Directions for use (v) Other information."
    ]
  },
  {
    "path":[
      903020000,
      1102090000
    ],
    "contexts":[
      " 9 Information to be included on the main label (3) Subject to paragraph (c), the name of the medicine and the name(s) of active ingredient(s) on the main label must: (b) not be separated by any text or graphics, except where additional information is: (i) required or permitted by: (A) paragraph 11(2)(h); or (B) subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A); or (C) subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit;",
      " 11 How information is to be expressed (2) Expression of quantity or proportion of active ingredients Subject to paragraph 11(2)(i) and subsection 11(3) below, the quantity or proportion of an active ingredient to be included on a label must be expressed: (i) In addition to the requirements of paragraphs 11(2)(a) \u201311(2)(g), the following requirements apply in the circumstances specified in the following subparagraphs: (i) where the active ingredient is a herbal material, such as a dry, fresh, milled or powdered herb, as the weight of the herbal material; except where standardisation is claimed on the label, then the minimum dry or fresh weight of herbal material and also the quantity of standardised constituents(s) in the herbal material; (ii) where the active ingredient is a herbal preparation, as the dry or fresh weight of the herbal material from which the preparation was derived except: (A) where standardisation of the herbal preparation is claimed on the label, then, the minimum dry or fresh weight of herbal material from which the preparation is derived and the quantity of standardised constituents(s) in the herbal preparation; or (B) where the active ingredient is a herbal preparation that is an essential oil; (iii) where the active ingredient is an enzyme \u2013the activity unit as specified in Column 1 of Schedule 3 to this Order in relation to a particular enzyme set out in Column 3 of that Schedule; (iv) for preparations containing Vitamin A or a derivative of Vitamin A - as the quantity or proportion of Vitamin A expressed in terms of microgram retinol equivalents; (v) for preparations containing biological organisms - as the number of organisms present per metric unit for liquids and powders and as the number of organisms present per dosage unit for other dosage forms;"
    ]
  },
  {
    "path":[
      1102080000,
      1102040000
    ],
    "contexts":[
      " 11 How information is to be expressed (2) Expression of quantity or proportion of active ingredients Subject to paragraph 11(2)(i) and subsection 11(3) below, the quantity or proportion of an active ingredient to be included on a label must be expressed: (h) for the purposes of paragraphs 11(2)(a) \u2013 11(2)(d), for oral preparations that contain active ingredients intended for mineral supplementation, it is sufficient that the quantity or proportion of that active ingredient to be included on a label be expressed as: (i) the name of the active ingredient; and (ii) the name and quantity of the element intended for mineral supplementation.",
      " 11 How information is to be expressed (2) Expression of quantity or proportion of active ingredients Subject to paragraph 11(2)(i) and subsection 11(3) below, the quantity or proportion of an active ingredient to be included on a label must be expressed: (d) for a medicine required to be prepared before use, and: (i) where the process results in a medicine that is a liquid for ingestion: (A) as the quantity of the active ingredient contained in the stated volume of a suitable dose of the liquid after preparation in accordance with the instructions set out on the label of the medicine; or (B) in the case where the medicine is one of a series of strengths containing the same active ingredient - as the quantity of the active ingredient contained in the stated volume of a suitable dose of the liquid after preparation in accordance with the instructions set out on the label of the medicine with the quantity or proportion of active ingredient expressed consistently across the series in terms of the same stated dose volume; and Example: Where the dose volume is 5 mL after preparation, and there are strengths of 1 mg\/mL and 5 mg\/mL, these must be labelled as 5 mg in 5 mL and 25 mg in 5 mL, respectively. (ii) for any other medicines - as the weight or volume of active ingredient in a stated weight or volume of the medicine, after preparation in accordance with the instructions included in the label of the medicine;"
    ]
  },
  {
    "path":[
      1008030000,
      800000000
    ],
    "contexts":[
      " 10 Qualifications and special requirements (8) Individually wrapped medicines (c) Where: (i) a medicine consists of dry herbs contained in individual bags and the bag is retained around the herbs during preparation; (ii) the bags are contained in a primary pack, the label of which complies with the requirements of this Order, then the individual bag need not be labelled with the information referred to in sections 8 and 9.",
      " 8 Information to be included on the label (4) If the information required on the label on the container is obscured by intermediate packaging, then the label on the intermediate packaging must include: (a) the name of the medicine; and"
    ]
  },
  {
    "path":[
      1102080000,
      1102020000
    ],
    "contexts":[
      " 11 How information is to be expressed (2) Expression of quantity or proportion of active ingredients Subject to paragraph 11(2)(i) and subsection 11(3) below, the quantity or proportion of an active ingredient to be included on a label must be expressed: (h) for the purposes of paragraphs 11(2)(a) \u2013 11(2)(d), for oral preparations that contain active ingredients intended for mineral supplementation, it is sufficient that the quantity or proportion of that active ingredient to be included on a label be expressed as: (i) the name of the active ingredient; and (ii) the name and quantity of the element intended for mineral supplementation.",
      " 11 How information is to be expressed (2) Expression of quantity or proportion of active ingredients Subject to paragraph 11(2)(i) and subsection 11(3) below, the quantity or proportion of an active ingredient to be included on a label must be expressed: (b) for a solid for ingestion, where there is no discrete dosage unit - as the quantity of the active ingredient contained in the stated weight of a suitable dose of the solid;"
    ]
  },
  {
    "path":[
      802050000,
      802030000
    ],
    "contexts":[
      " 8 Information to be included on the label (2) (e) If information other than the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be included, it must be placed under the \u2018Other information\u2019 heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b) and must not contain any additional information other than: A. requirements relating to storage conditions B. information about package features to prevent tampering C. names of all excipients D. sponsor or distributor contact details.",
      " 8 Information to be included on the label (2) (c) The information provided under paragraph 8(2)(b)(i) may include words describing the purpose of the active ingredient(s) by indicating the pharmacological category or the principal intended actions that are not required by this Order."
    ]
  },
  {
    "path":[
      910030000,
      913000000
    ],
    "contexts":[
      " 9 Information to be included on the main label (10) Subsection 9(9) does not apply: (c) where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(13) and Part 2 of Schedule 2\u2014after 30 April 2028. Note: The minimum text size for active ingredients on labels of small containers is less than 2.5 millimetres and specified elsewhere in this Order.",
      " 9 Information to be included on the main label (13) An active ingredient specified in Part 2 of Schedule 2, either alone or in combination with any other descriptors, may be included on the main label of a medicine containing that ingredient as specified in that Part for medicine released for supply before 1 May 2028."
    ]
  },
  {
    "path":[
      908030000,
      906020000
    ],
    "contexts":[
      " 9 Information to be included on the main label (8) Where a medicine is: (c) (i) the total number of active ingredients in the different formulations in the composite pack or medicine kit are to be counted; and (ii) if the same active ingredient is contained in two or more formulations in the composite pack or medicine kit, each of those active ingredients is to be counted separately, for the purposes of determining if paragraph 9(6)(b) applies to the composite pack or medicine kit, or which paragraph in subsection 9(7) applies to the composite pack or medicine kit; and",
      " 9 Information to be included on the main label (6) If the medicine is intended to be, or is, listed goods: (b) if there are four or more active ingredients in the medicine - the name of every active ingredient, together with the quantity or proportion of every active ingredient, may appear on a side panel or side label or on a rear panel or rear label."
    ]
  },
  {
    "path":[
      302020000,
      500000000
    ],
    "contexts":[
      "3 Application - Therapeutic goods to which this Order applies(2) To avoid doubt, this Order will apply to the following medicines:(b) medicines exempt from the listing and registration requirements, other than those specified in section 5 of this Order.",
      "5 Exemptions \u2013 Medicines to which this Order does not apply (2) The requirements of this Order do not apply to a transparent covering that encloses or wraps the container or primary pack containing a medicine and where the information that is required to be set out on the label of the container or the primary pack is clearly visible through that transparent covering."
    ]
  },
  {
    "path":[
      802050000,
      802040000
    ],
    "contexts":[
      " 8 Information to be included on the label (2) (e) If information other than the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be included, it must be placed under the \u2018Other information\u2019 heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b) and must not contain any additional information other than: A. requirements relating to storage conditions B. information about package features to prevent tampering C. names of all excipients D. sponsor or distributor contact details.",
      " 8 Information to be included on the label (2) (d) The information provided under paragraph 8(2)(b)(iii) may include safety related information not required by this Order (such as allergen advice, caution, additional warning or advisory statements)."
    ]
  },
  {
    "path":[
      403000000,
      402000000
    ],
    "contexts":[
      "4 Transition arrangements (3) Notwithstanding (1) and (2), medicines imported into or manufactured in Australia before 1 September 2020 but supplied by a person other than the sponsor after that date must comply with TGO 69 (2017) if at the time of their release for supply they complied with TGO 69 (2017).",
      "4 Transition arrangements (2) On and from 1 September 2020, each medicine to which this Order applies must comply with the requirements specified in this Order."
    ]
  },
  {
    "path":[
      301000000,
      500000000
    ],
    "contexts":[
      "3 Application - Therapeutic goods to which this Order applies(1) Subject to sections 4 and 5, this Order applies to medicines supplied or for supply in Australia, other than those specified under section 3 of the Therapeutic Goods Order No. 91 \u2013 Standard for labels of prescription and related medicines.",
      "5 Exemptions \u2013 Medicines to which this Order does not apply (2) The requirements of this Order do not apply to a transparent covering that encloses or wraps the container or primary pack containing a medicine and where the information that is required to be set out on the label of the container or the primary pack is clearly visible through that transparent covering."
    ]
  },
  {
    "path":[
      1102080000,
      1102030000
    ],
    "contexts":[
      " 11 How information is to be expressed (2) Expression of quantity or proportion of active ingredients Subject to paragraph 11(2)(i) and subsection 11(3) below, the quantity or proportion of an active ingredient to be included on a label must be expressed: (h) for the purposes of paragraphs 11(2)(a) \u2013 11(2)(d), for oral preparations that contain active ingredients intended for mineral supplementation, it is sufficient that the quantity or proportion of that active ingredient to be included on a label be expressed as: (i) the name of the active ingredient; and (ii) the name and quantity of the element intended for mineral supplementation.",
      " 11 How information is to be expressed (2) Expression of quantity or proportion of active ingredients Subject to paragraph 11(2)(i) and subsection 11(3) below, the quantity or proportion of an active ingredient to be included on a label must be expressed: (c) subject to paragraph (d) below, if the medicine is a liquid for ingestion: (i) as the quantity of the active ingredient contained in the stated volume of a suitable dose of the liquid; or (ii) in the case where the liquid for ingestion is one of a series of strengths containing the same active ingredient \u2013 as the quantity of the active ingredient contained in the stated volume of a suitable dose of the liquid with the quantity or proportion of active ingredient expressed consistently across the series in terms of the same stated dose volume. Example: Where the dose volume is 5 mL, and there are strengths of 1 mg\/mL and 5 mg\/mL, these must be labelled as 5 mg in 5 mL and 25 mg in 5 mL, respectively."
    ]
  },
  {
    "path":[
      903020000,
      1102080000
    ],
    "contexts":[
      " 9 Information to be included on the main label (3) Subject to paragraph (c), the name of the medicine and the name(s) of active ingredient(s) on the main label must: (b) not be separated by any text or graphics, except where additional information is: (i) required or permitted by: (A) paragraph 11(2)(h); or (B) subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A); or (C) subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit;",
      " 11 How information is to be expressed (2) Expression of quantity or proportion of active ingredients Subject to paragraph 11(2)(i) and subsection 11(3) below, the quantity or proportion of an active ingredient to be included on a label must be expressed: (h) for the purposes of paragraphs 11(2)(a) \u2013 11(2)(d), for oral preparations that contain active ingredients intended for mineral supplementation, it is sufficient that the quantity or proportion of that active ingredient to be included on a label be expressed as: (i) the name of the active ingredient; and (ii) the name and quantity of the element intended for mineral supplementation."
    ]
  },
  {
    "path":[
      802030000,
      802020000
    ],
    "contexts":[
      " 8 Information to be included on the label (2) (c) The information provided under paragraph 8(2)(b)(i) may include words describing the purpose of the active ingredient(s) by indicating the pharmacological category or the principal intended actions that are not required by this Order.",
      " 8 Information to be included on the label (2) (b) The critical health information must be presented under appropriate headings and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Directions for use (v) Other information."
    ]
  },
  {
    "path":[
      601150000,
      801100000
    ],
    "contexts":[
      "6 Interpretation. \"critical health information\" means information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of this Order, that is critical for safe use of medicines that are self-selected by a consumer;",
      " 8 Information to be included on the label (1) Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include: (j) where: (i) a substance or substance within the group of substances referred to in Column 1 of Schedule 1 to this Order is present in the medicine; (ii) the circumstances as set out in Column 2 of Schedule 1 exist in relation to such a substance or no circumstances are set out in Column 2; and (iii) the medicine is intended to be administered via any one or more of the route(s) of administration referred to in Column 3 of Schedule 1, then: (iv) a statement: (A) indicating that the medicine contains the substance expressed using the Name stated in Column 4 of Schedule 1; and (B) where any of the circumstances and requirements set out in Column 2 of Schedule 1 exist in relation to the substance \u2013 a statement of the kind referred to as a \u2018requirement\u2019 in that Column (if any); and"
    ]
  },
  {
    "path":[
      910000000,
      909000000
    ],
    "contexts":[
      " 9 Information to be included on the main label (10) Subsection 9(9) does not apply: (b) where the medicine is not supplied in a small container and is labelled in accordance with subsection 9(11) and Part 1 of Schedule 2\u2014after 30 April 2026; or",
      " 9 Information to be included on the main label (9) If the medicine is intended to be, or is, registered goods, and the name of an active ingredient included in the medicine comprises an ingredient name specified in Schedule 2 to this Order, either alone or in combination with any other descriptors, then the names of all active ingredients in the medicine, together with their quantity or proportion, must be displayed in a text size of not less than 2.5 millimetres."
    ]
  },
  {
    "path":[
      1009020000,
      800000000
    ],
    "contexts":[
      " 10 Qualifications and special requirements (9) Strip, blister and dial dispenser packs (b) If, in relation to a medicine referred to in (a) there are: (i) four or more active ingredients in the medicine and the medicine is intended to be, or is, registered goods; or (ii) two or more active ingredients in the medicine and the medicine is intended to be, or is, listed goods, then, in relation to compliance of the label on the strip, blister or dial dispenser pack with sections 8 and 9, it shall be sufficient if the following information is displayed: (iii) the name of the medicine; and (iv) the batch number of the medicine preceded by the batch number prefix; and (v) the expiry date of the medicine preceded by the expiry date prefix; and (vi) the name of the sponsor or distributor, or registered trademark if it readily identifies the sponsor or distributor of the medicine.",
      " 8 Information to be included on the label (1) Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include: (n) a statement of the purpose or purposes for which it is intended that the medicine be used, except where: (i) the medicine is: (A) supplied solely to a complementary healthcare practitioner for supply to a person after affixing by the practitioner of an instruction label on the medicine following a consultation with that person; and (B) the label of the medicine includes the words \u2018For Practitioner Dispensing Only\u2019; and"
    ]
  },
  {
    "path":[
      908040000,
      906020000
    ],
    "contexts":[
      " 9 Information to be included on the main label (8) Where a medicine is: (d) the information required under either paragraph 9(6)(b) or subsection 9(7) must be provided separately in relation to each formulation of medicine in the composite pack or medicine kit.",
      " 9 Information to be included on the main label (6) If the medicine is intended to be, or is, listed goods: (b) if there are four or more active ingredients in the medicine - the name of every active ingredient, together with the quantity or proportion of every active ingredient, may appear on a side panel or side label or on a rear panel or rear label."
    ]
  },
  {
    "path":[
      1103030000,
      1103020000
    ],
    "contexts":[
      " 11 How information is to be expressed (3) Expression of quantity or proportion of active ingredients for homoeopathic preparations The label on the container and on the primary pack of a medicine that contains a homoeopathic preparation must include: (c) where paragraphs (a) and (b) do not apply- the quantity of the preparation in one millilitre or in one gram of the medicine",
      " 11 How information is to be expressed (3) Expression of quantity or proportion of active ingredients for homoeopathic preparations The label on the container and on the primary pack of a medicine that contains a homoeopathic preparation must include: (b) where all active ingredients of the medicine are homoeopathic preparations and are all included in the medicine in the same proportion - as \u2018Contains equal parts of ...\u2019 followed by the name of each active ingredient; or"
    ]
  },
  {
    "path":[
      903020000,
      1105000000
    ],
    "contexts":[
      " 9 Information to be included on the main label (3) Subject to paragraph (c), the name of the medicine and the name(s) of active ingredient(s) on the main label must: (b) not be separated by any text or graphics, except where additional information is: (i) required or permitted by: (A) paragraph 11(2)(h); or (B) subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A); or (C) subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit;",
      " 11 How information is to be expressed (5) Inclusion of common names of vitamins Where a medicine contains an active ingredient that is a vitamin, then the word \u2018vitamin\u2019, or any suitable unambiguous abbreviation of the word vitamin, together with the common name of that vitamin, may appear on a main label of the medicine either: (b) on a separate line of text - immediately below the related name of the active ingredient that is a vitamin and the quantity of that active ingredient."
    ]
  },
  {
    "path":[
      1007000000,
      900000000
    ],
    "contexts":[
      " 10 Qualifications and special requirements (7) Small containers If: (j) the expiry date of the medicine preceded by the expiry date prefix; and",
      " 9 Information to be included on the main label (3) Subject to paragraph (c), the name of the medicine and the name(s) of active ingredient(s) on the main label must: (b) not be separated by any text or graphics, except where additional information is: (i) required or permitted by: (A) paragraph 11(2)(h); or (B) subparagraphs 11(2)(i)(i) or 11(2)(i)(ii)(A); or (C) subsection 11(5); or (ii) in relation to identifying the different formulations of the medicines contained in a composite pack or a medicine kit;"
    ]
  },
  {
    "path":[
      301000000,
      400000000
    ],
    "contexts":[
      "3 Application - Therapeutic goods to which this Order applies(1) Subject to sections 4 and 5, this Order applies to medicines supplied or for supply in Australia, other than those specified under section 3 of the Therapeutic Goods Order No. 91 \u2013 Standard for labels of prescription and related medicines.",
      "4 Transition arrangements (3) Notwithstanding (1) and (2), medicines imported into or manufactured in Australia before 1 September 2020 but supplied by a person other than the sponsor after that date must comply with TGO 69 (2017) if at the time of their release for supply they complied with TGO 69 (2017)."
    ]
  },
  {
    "path":[
      1008020000,
      900000000
    ],
    "contexts":[
      " 10 Qualifications and special requirements (8) Individually wrapped medicines (b) If: (i) the medicine consists only of pastilles or lozenges; and (ii) each dosage unit is enclosed in an unsealed individual wrapper; and (iii) each dosage unit is, after being so wrapped, enclosed in a primary pack that complies with sections 8 and 9, then, in relation to compliance of the label for each individual wrapper with sections 8 and 9, it shall be sufficient if the name of the medicine is displayed.",
      " 9 Information to be included on the main label (9) If the medicine is intended to be, or is, registered goods, and the name of an active ingredient included in the medicine comprises an ingredient name specified in Schedule 2 to this Order, either alone or in combination with any other descriptors, then the names of all active ingredients in the medicine, together with their quantity or proportion, must be displayed in a text size of not less than 2.5 millimetres."
    ]
  },
  {
    "path":[
      1005000000,
      800000000
    ],
    "contexts":[
      " 10 Qualifications and special requirements (5) Sunscreen preparations If: (a) the medicine is a sunscreen preparation; and",
      " 8 Information to be included on the label (1) Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include: (l) directions for use of the medicine except where: (i) the dose of the medicine is usually determined for each individual patient by a health professional authorised under a law of a State or Territory to determine the dose; or (ii) there is insufficient space on the label of either the container or the primary pack, or both, to include directions for use, and: (A) those directions for use are set out in a package insert provided in the primary pack of the medicine; and (B) a statement is included on whichever label on the container, or the primary pack, or both, that does not set out the directions for use itself, that those directions are set out in the package insert; and"
    ]
  },
  {
    "path":[
      601150000,
      801020000
    ],
    "contexts":[
      "6 Interpretation. \"critical health information\" means information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of this Order, that is critical for safe use of medicines that are self-selected by a consumer;",
      " 8 Information to be included on the label (1) Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include: (b) the name(s) of all active ingredients in the medicine; and"
    ]
  },
  {
    "path":[
      903030000,
      903010000
    ],
    "contexts":[
      " 9 Information to be included on the main label (3) Subject to paragraph (c), the name of the medicine and the name(s) of active ingredient(s) on the main label must: (c) if the medicine is: (i) supplied in either a small or a medium container; and (ii) contains multiple active ingredients then, in relation to compliance of the label with paragraph 9(3)(a), the names of the multiple active ingredients and their quantities may be presented together on a continuous line, or lines, of text.",
      " 9 Information to be included on the main label (3) Subject to paragraph (c), the name of the medicine and the name(s) of active ingredient(s) on the main label must: (a) appear as a cohesive unit by the placing of the name and quantity of each active ingredient together on separate lines of text either (i) immediately below the name of the medicine; or (ii) where the trademark of the medicine might be disrupted or obscured, adjacent to the name of the medicine; and"
    ]
  },
  {
    "path":[
      1103030000,
      1103010000
    ],
    "contexts":[
      " 11 How information is to be expressed (3) Expression of quantity or proportion of active ingredients for homoeopathic preparations The label on the container and on the primary pack of a medicine that contains a homoeopathic preparation must include: (c) where paragraphs (a) and (b) do not apply- the quantity of the preparation in one millilitre or in one gram of the medicine",
      " 11 How information is to be expressed (3) Expression of quantity or proportion of active ingredients for homoeopathic preparations The label on the container and on the primary pack of a medicine that contains a homoeopathic preparation must include: (a) where the medicine is a fully potentised, single ingredient, homoeopathic medicine and it is clear that the ingredient comprises 100% of the medicine \u2013 the name of the active ingredient; or"
    ]
  },
  {
    "path":[
      601150000,
      801120000
    ],
    "contexts":[
      "6 Interpretation. \"critical health information\" means information required under paragraphs 8(1)(b), (c), (j), (k), (l) and (n) of this Order, that is critical for safe use of medicines that are self-selected by a consumer;",
      " 8 Information to be included on the label (1) Subject to the qualifications and requirements specified in subsections 8(2) and 8(3) and sections 9 and 10 below, the labels of a medicine must include: (l) directions for use of the medicine except where: (i) the dose of the medicine is usually determined for each individual patient by a health professional authorised under a law of a State or Territory to determine the dose; or (ii) there is insufficient space on the label of either the container or the primary pack, or both, to include directions for use, and: (A) those directions for use are set out in a package insert provided in the primary pack of the medicine; and (B) a statement is included on whichever label on the container, or the primary pack, or both, that does not set out the directions for use itself, that those directions are set out in the package insert; and"
    ]
  },
  {
    "path":[
      802050000,
      802020000
    ],
    "contexts":[
      " 8 Information to be included on the label (2) (e) If information other than the critical health information or information of a kind mentioned in subsections 8(2)(c) or 8(2)(d) is to be included, it must be placed under the \u2018Other information\u2019 heading or under another separate appropriate heading(s) that follow immediately below the headings mentioned in 8(2)(b) and must not contain any additional information other than: A. requirements relating to storage conditions B. information about package features to prevent tampering C. names of all excipients D. sponsor or distributor contact details.",
      " 8 Information to be included on the label (2) (b) The critical health information must be presented under appropriate headings and in the following order: (i) Active ingredients (ii) Indications (iii) Warnings (iv) Directions for use (v) Other information."
    ]
  },
  {
    "path":[
      908040000,
      907000000
    ],
    "contexts":[
      " 9 Information to be included on the main label (8) Where a medicine is: (d) the information required under either paragraph 9(6)(b) or subsection 9(7) must be provided separately in relation to each formulation of medicine in the composite pack or medicine kit.",
      " 9 Information to be included on the main label (7) Subject to subsection 9(9), if the medicine is intended to be, or is, registered goods, then: (c) where the medicine contains four or more active ingredients and subsection 8(2) applies, then compliance with paragraphs 9(1)(b) and 9(1)(c) is not required; or"
    ]
  }
]